Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Post author: Post published:March 1, 2026 Post category: Continue ReadingLong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs Post author: Post published:March 1, 2026 Post category: Continue ReadingLeading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Post author: Post published:March 1, 2026 Post category: Continue ReadingT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme Post author: Post published:March 1, 2026 Post category: Continue ReadingB7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
CAR-T Long Term Follow Up (LTFU) Study Post author: Post published:March 1, 2026 Post category: Continue ReadingCAR-T Long Term Follow Up (LTFU) Study
SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer Post author: Post published:March 1, 2026 Post category: Continue ReadingA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
